Neuropathic Ocular Pain Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Novartis, OKYO Pharma, AbbVie Inc., Aciex, Novartis

DelveInsight’s “Neuropathic Ocular Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neuropathic Ocular Pain, historical and forecasted epidemiology as well as the Neuropathic Ocular Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Neuropathic Ocular Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuropathic Ocular Pain Market Forecast

Some of the key facts of the Neuropathic Ocular Pain Market Report: 

• The Neuropathic Ocular Pain market size was valued approximately USD 99 Million in the year 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to Aggarwal et al. (2020), 3.7 million cataract cases were estimated to have been performed in 2020 in the United States among Medicare beneficiaries
• As per the data given by La Informacion (n.d.), in Spain, nearly 105,000 patients are undergoing refractive surgeries each year
• According to DelveInsight’s estimate, the total cases of Neuropathic Ocular Pain (NOP) in the 7MM comprised ~3,069,300 cases in 2022. These cases are anticipated to increase during the study period
• In 2022, the total cases of Neuropathic Ocular Pain (NOP) in the Japan comprised ~701,600 cases in 2022. These cases are anticipated to decrease during the study period
• In EU4 and the UK, the highest number of total cases of Neuropathic Ocular Pain (NOP) was observed in Italy with ~534,200 cases in 2022 whereas least cases were observed in Spain with ~192,200 cases in 2022
• Key Neuropathic Ocular Pain Companies: Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies, MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Ltd., SALVAT, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care., Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals, BRIM Biotechnology, Inc., and others
• Key Neuropathic Ocular Pain Therapies: SAF312, OK-201, Lidocaine, Ketamine, Nerve stimulation, Gene Therapy, Gabapentin, Pregabalin, and others
• The Neuropathic Ocular Pain epidemiology based on gender analyzed that Neuropathic Ocular Pain (NOP) affects males and female equally
• The Neuropathic Ocular Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuropathic Ocular Pain pipeline products will significantly revolutionize the Neuropathic Ocular Pain market dynamics.

Neuropathic Ocular Pain Overview

Neuropathic ocular pain (NOP), also referred to as corneal neuropathic pain, is a condition in which corneal pain is seen in response to normally non-painful stimuli. This pain results from repeated direct damage to corneal nerves.

Get a Free sample for the Neuropathic Ocular Pain Market Report – 

https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market

Neuropathic Ocular Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neuropathic Ocular Pain Epidemiology Segmentation:

The Neuropathic Ocular Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Neuropathic Ocular Pain
• Prevalent Cases of Neuropathic Ocular Pain by severity
• Gender-specific Prevalence of Neuropathic Ocular Pain
• Diagnosed Cases of Episodic and Chronic Neuropathic Ocular Pain

Download the report to understand which factors are driving Neuropathic Ocular Pain epidemiology trends @ Neuropathic Ocular Pain Epidemiology Forecast

Neuropathic Ocular Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuropathic Ocular Pain market or expected to get launched during the study period. The analysis covers Neuropathic Ocular Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neuropathic Ocular Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neuropathic Ocular Pain Therapies and Key Companies

• SAF312: Novartis
• OK-201: OKYO Pharma
• Lidocaine: Aciex Therapeutics
• Ketamine: Novaliq
• Nerve stimulation: Oculeve and Allergan
• Gene Therapy: Adverum Biotechnologies and MeiraGTx
• Gabapentin: Ocular Therapeutix
• Pregabalin: Aldeyra Therapeutics

Discover more about therapies set to grab major Neuropathic Ocular Pain market share @ Neuropathic Ocular Pain Treatment Market

Scope of the Neuropathic Ocular Pain Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neuropathic Ocular Pain Companies: Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies, MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Ltd., SALVAT, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care., Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals, BRIM Biotechnology, Inc., and others
• Key Neuropathic Ocular Pain Therapies: SAF312, OK-201, Lidocaine, Ketamine, Nerve stimulation, Gene Therapy, Gabapentin, Pregabalin, and others
• Neuropathic Ocular Pain Therapeutic Assessment: Neuropathic Ocular Pain current marketed and Neuropathic Ocular Pain emerging therapies
• Neuropathic Ocular Pain Market Dynamics: Neuropathic Ocular Pain market drivers and Neuropathic Ocular Pain market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Neuropathic Ocular Pain Unmet Needs, KOL’s views, Analyst’s views, Neuropathic Ocular Pain Market Access and Reimbursement 

To know more about Neuropathic Ocular Pain companies working in the treatment market, visit @ Neuropathic Ocular Pain Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Neuropathic Ocular Pain Market Report Introduction

2. Executive Summary for Neuropathic Ocular Pain

3. SWOT analysis of Neuropathic Ocular Pain

4. Neuropathic Ocular Pain Patient Share (%) Overview at a Glance

5. Neuropathic Ocular Pain Market Overview at a Glance

6. Neuropathic Ocular Pain Disease Background and Overview

7. Neuropathic Ocular Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Neuropathic Ocular Pain 

9. Neuropathic Ocular Pain Current Treatment and Medical Practices

10. Neuropathic Ocular Pain Unmet Needs

11. Neuropathic Ocular Pain Emerging Therapies

12. Neuropathic Ocular Pain Market Outlook

13. Country-Wise Neuropathic Ocular Pain Market Analysis (2019–2032)

14. Neuropathic Ocular Pain Market Access and Reimbursement of Therapies

15. Neuropathic Ocular Pain Market Drivers

16. Neuropathic Ocular Pain Market Barriers

17.  Neuropathic Ocular Pain Appendix

18. Neuropathic Ocular Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services